Table 10 HIV/AIDS
From: Benefits and harms of medical cannabis: a scoping review of systematic reviews
Author, year {refid} | Search dates; # databases searched | Funding source | Nstudies | Illness/condition | Intervention/comparator | Outcomes | Conclusions from data | AMSTAR-2 rating |
|---|---|---|---|---|---|---|---|---|
Lutge, 2013 [48] | 1980–Jul 2012; 7 | NR | 7 | HIV/AIDS | I: Plant-based and synthetic cannabinoids C: Placebo | • Change in body fat • Appetite • Food/caloric intake • Nausea and vomiting • Performance • Mood • Subjective experience of drug • Peripheral NP • Effect on pharmacokinetics of protease inhibitors • Viral load and CD4 count • Resting heart rate • Skin temperature • Withdrawal due to adverse events | Reported SBS for all outcomes except change in mood, which found no statistically significant difference between groups | M |
Phillips, 2010 [53] | Search on Jun 20, 2008 and updated Feb 22, 2010; 4 | Non-profit | 2 | HIV | I: Plant-based cannabis C: placebo | • NP | Favors intervention | CL |
Merlin, 2016 [67] | Inception to Jan 2015; CENTRAL: Jun 2014; 5 | Government | 1 | HIV | I: Plant-based cannabis C: Placebo | • NP | Reported SBS | CL |